Abstract
We thank Dr Cen for his thoughtful comments about our work.1,2 He suggests combining covariates from the Adenoma Prevention With Celecoxib (APC) and Prevention of Colorectal Sporadic Adenomatous Polyps (PreSAP) trials into a single Cox model and using the resulting hazard ratio to estimate the overall effect of celecoxib on cardiovascular end points. This approach treats the variable trial (APC or PreSAP) as 1 ingredient in a stew. We believe in maintaining the integrity of the ingredients as long as possible to allow the flavor of each trial to retain its unique contribution. …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
